Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax plus ibrutinib in relapsed/refractory T-cell prolymphocytic leukemia
2018-002179-17Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax and ibrutinib in T-cell prolymphocytic leukemia (T-PLL), sponsored by AbbVie Inc. Primary endpoint: Overall response rate (ORR). Started Aug 2019; status: completed.
02
Drugs
venetoclaxibrutinib
03
Conditions
T-cell prolymphocytic leukemia (T-PLL)
Beyond the preview
Go deeper on 2018-002179-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002179-17.